You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Business & Finance
Lilly declares Q2 2025 dividend
6 May 2025 -

The board of directors of pharmaceutical company Eli Lilly and Company (NYSE:LLY) on Monday declared a dividend of USD1.50 per share of common stock for the second quarter of 2025.

This amount is unchanged from the first quarter.

Shareholders of record at the close of business on 16 May 2025 will receive the dividend on 10 June 2025.

Login
Username:

Password:


Related Headlines

Genomma Lab Internacional announces Q2 2025 results

Sanofi finalizes acquisition of Blueprint Medicines to expand rare disease and immunology portfolio

Perrigo to divest Dermacosmetics business for up to EUR327m

CVS Health declares quarterly dividend USD0.665 per share

Lilly declares dividend of USD1.50 for Q3

Bavarian Nordic sells US Priority Review Voucher for USD160m

Bavarian Nordic sells US Priority Review Voucher for USD160m

FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea

Sanofi to acquire Blueprint Medicines in USD9.5bn rare disease deal

Eisai forecasts 73% Leqembi revenue growth in FY 2025, boosting BioArctic royalties

ValiRx subsidiary Inaphaea extends drug repurposing deal with Dominion Biotech

Bavarian Nordic secures USD143.6m US government contract for freeze-dried smallpox/mpox vaccine supply

Lilly declares Q2 2025 dividend

Bruker acquires majority stake in RECIPE to expand clinical mass spectrometry diagnostics

Emmaus Life Sciences reports drop in revenues, increased loss in 2024

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2025